These 2 Unstoppable Stocks Could Make You Richer in 2024 and Beyond
Although one of the top investment themes of 2023 was artificial intelligence (AI), there were several other serious contenders. The weight-loss market has emerged as a hot growth area, with diabetes and obesity treatments on the rise -- and the majority of top-branded medications are developed by just two companies.
Let's take a closer look at this duo in the pharmaceutical industry that are dominating the weight-loss market and assess why each stock presents an intriguing long-term buying opportunity.
If you aren't familiar with Novo Nordisk (NYSE: NVO), odds are you've seen the commercials or heard the catchy jingles for its various weight-loss medications. Novo Nordisk is a Danish pharmaceutical company and the developer behind Ozempic, Wegovy, Rybelsus, and Saxenda.
Source Fool.com
